30 closest matches · ranked by relevance
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB) — 100; 100; 100 percentage of surviving patients
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia-2 · High Grade Malignant Neoplasm
Primary: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant — 9; 21 Participants
Blood Cancer · Leukemia · Graft Versus Host Disease
Primary: Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and…
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 5; 3; 10; 17 participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912) — 22; 39; 43 percentage of participants
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
Severe Osteopetrosis
Primary: Number of Patients Who Achieved Donor Cell Engraftment — 5; 0 Participants
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndromes
Primary: Number of Participants Achieving Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) Through 1 Year Post-Transplant — 4 Participants
Leukemia
Primary: Overall Response (OR) Post Transplant — 1; 6; 0 Participants
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Hematologic Malignancy
Primary: Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT) — 5 Participants
Sickle Cell Disease & Thalassemia
Primary: Safety and Tolerability Will be Measured by Acute NiCord® Infusional Toxicity. — 0; 0; 3; 0 participants
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 21; 25 participants
Hematological Neoplasms · Hematopoietic Stem Cell Transplantation
Primary: Number of Participants Experiencing Transplant Related Mortality (TRM) — 0 Participants
Hemoglobinopathies · Sickle Cell Disease · Thalassemia
Primary: Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy. — 2 participants
Sickle Cell Anemia · Severe Aplastic Anemia · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Patients With Neutrophil Engraftment — 2 participants
Acute Myelogenous Leukemia · Lymphoid Leukemia · Chronic Myelogenous Leukemia
Primary: Median Disease-free Survival — 333 Days
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants